Potomac, MD, United States of America

Bette S Pollard

This inventor holds 5 USPTO granted patents and 1 published patent application. Top assignee: Other. Active years: 2001-2016.

USPTO Granted Patents = 5 

% Patents Active = 80.0

Average Co-Inventor Count = 1.3

ph-index = 1

Forward Citations = 12(Granted Patents)


Location History:

  • Rockville, MD (US) (2013)
  • Potomac, MD (US) (2001 - 2016)

Company Filing History:

goldMedal5 out of 834,411 
Other
 patents

Years Active: 2001-2016

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Bette S Pollard: Innovator in Medical Treatments

Introduction

Bette S Pollard is a notable inventor based in Potomac, MD (US). She has made significant contributions to the field of medical treatments, particularly in addressing complex health conditions through innovative pharmaceutical compositions. With a total of 5 patents, her work has the potential to impact the lives of many patients.

Latest Patents

One of her latest patents focuses on cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders. This invention discloses the use of a cardiac glycoside to decrease or inhibit the secretion of proinflammatory mediators in disease conditions characterized by elevated levels of these mediators. The cardiac glycoside is administered to a mammalian subject in need of treatment, with dosage adjusted according to the recipient's mass and specific needs. The proinflammatory mediators suppressed by this invention include IL-8, IL-6, TNFalpha, ICAM-1, IFNgamma, IL-1-beta, MCP-1, MIP-2, and/or epithelial-mesenchymal-transition (EMT). The cardiac glycoside, which can be digitoxin or oleandrin, may be formulated for various methods of administration, including injection, aerosol, ingestion, or nasal spray. Additionally, digitoxin has been shown to control microRNA expression in castration-resistant prostate cancer, suppressing IL-8 and IL-6 expression in these cells.

Another significant patent involves amphiphilic pyridinium compounds for treating epilepsy and other disorders of the nervous system. This pharmaceutical composition is designed to treat neurological disorders or seizure disorders, particularly epilepsy. It can be used as a primary treatment or as an adjuvant treatment. The administration of the amphiphilic pyridinium compound(s) may occur before the manifestation of symptoms characteristic of epilepsy, thereby preventing or delaying its progression.

Career Highlights

Bette S Pollard has established herself as a leading figure in the development of innovative medical treatments. Her research and inventions have garnered attention for their potential to improve patient outcomes in various health conditions.

Collaborations

Bette collaborates with her coworker, Harvey B Pollard, to further advance their research and innovations in the medical field.

Conclusion

Bette S Pollard's contributions to medical innovations through her patents

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…